NCT01764737View on ClinicalTrials.gov

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Multiple Sclerosis
Interventions
DRUG

VX15/2503

single dose intravenous administration

DRUG

Placebo

single dose intravenous administration

Trial Locations (10)

12110

MS Center of Northeastern NY/Empire Neurology, Latham

14642

University of Rochester Medical Center, Rochester

28204

The Neurological Institute, PA, Charlotte

35058

North Central Neurology Associates, PC, Cullman

44195

The Cleveland Clinic Foundation, Cleveland

46202

Indiana University Health Neuroscience Center, Indianapolis

48201

Wayne State University - University Health Center, Detroit

66160

University of Kansas Medical Center, Kansas City

80045

University of Colorado Hospital, Aschutz Inpatient Pavilion, Aurora

98122

Swedish Medical Center, Seattle

Sponsors

Collaborators (1)

PRA Health Sciences
All Listed Sponsors
collaborator

PRA Health Sciences

INDUSTRY

lead

Vaccinex Inc.

INDUSTRY

NCT01764737 - Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS | Biotech Hunter | Biotech Hunter